Categories AlphaGraphs, Earnings, Health Care

REGN Earnings: Regeneron Pharma reports higher Q2 profit and revenue

Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the second quarter of 2023.

Regeneron Pharmaceuticals Q2 2023 earnings infographic

June quarter revenues grew 11% year-over-year to $3.16 billion. Net product sales, which account for more than 50% of total revenues, edged up 1%.

Adjusted earnings moved up 5% to $10.24 per share in Q2 from $9.77 per share in the same period of 2022. Unadjusted profit was $968 million or $8.50 per share, compared to $852 million or $7.47 per share last year.

“We remain focused on advancing our robust pipeline at all stages, and we were pleased to announce positive data from a late-stage study of Dupixent in COPD and make continued progress with our costimulatory and bispecific antibody candidates in oncology,” said the company’s CEO Leonard Schleifer,” said the company’s CEO Leonard Schleifer.

Prior Performance

  • Regeneron Pharmaceuticals Q4 2022 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results

Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where

What to look for when United Airlines (UAL) reports its Q4 2025 earnings results

Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for

Infographic: How Constellation Brands (STZ) performed in Q3 2026

Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top